DPHARM Idol Presenting Companies Announced to Compete for Most Disruptive New Company in Clinical Trials
DPHARM: Disruptive Innovations to Modernize Clinical Research
DPHARM is the most established program applying disruptive thinking to shake up the way we do clinical trials.
The Conference Forum announced the 2023 presenting companies who will compete for the title of most innovative new company to disrupt clinical trial operations at DPHARM: Disruptive Innovations to Modernize Clinical Research conference in Boston, MA on September 21, 2023.?
The presenting pre-approved companies will pitch how they are solving problems in clinical trials in front of 15 judges representing R&D executives, patient advocates, and life science investors.
“DPHARM Idol Disrupt puts the spotlight on a few fearless companies rewriting the rules of patient-centric breakthroughs. The winning company will inspire us with their unwavering determination and potential for reshaping the landscape of clinical trials and healthcare at large,” said Bert Hartog, PhD, MSc, Senior Director, Janssen Clinical Innovation, Janssen Research & Development and 2023 DPHARM Idol Disrupt judge.?
The six DPHARM Idol Disrupt 2023 contenders are:?
Narrativa Generative AI is an internationally recognized B2B AI company that empowers teams of all sizes to build and deploy smart composition, business intelligence reporting, process optimization content solutions, regulatory documentation, and more using its proprietary Generative AI Platform consisting of data extraction, data analysis, NLP, and NLG tools.?
Faro Health is bringing clinical trials into the digital age by helping teams manage and balance the complexity of modern trial designs through a cloud native platform. The Faro platform enables study teams to design complex clinical trials using small modular building blocks and combines that with data driven insights to orchestrate and automate operationally complex trials.?
Eko Health advances how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform allows professionals to detect earlier and more accurately, diagnose more confidently, manage treatment effectively, and give patients the best care possible.?
Phesi’s patient-centric data analytics solutions can help deliver smarter trials and faster cures. Their Trial Accelerator? platform, powered by the world’s largest trials database, can simulate clinical trials and generate Digital Patient Profiles and Digital Twins, inform program and protocol design, and improve country and investigator site performance.?
Readout AI turns clinical trial data into insights, automatically. The AI applies appropriate biostatics to raw data, and then describes the findings in paragraphs for clinical study reports, abstracts or even posters. Readout AI turbocharges medical writing and biostatistics, shrinking the time to turn raw clinical data into actionable outputs.?
领英推荐
Nurocor is the leading technology vendor for digital protocol innovation. The Nurocor Clinical Platform enables companies to streamline the digital flow of clinical information from protocol to regulatory submission. This process can save clinical development organizations, conservatively, $8M and 8 months on the median Phase 3 study.
DPHARM Idol Disrupt 2023 judges are:?
Past DPHARM Idol winners include:?
Acclinate , 2022
Biofourmis , 2021
Tasso, Inc. , 2019
Medable, Inc , 2018
physIQ , 2017
Florence Healthcare , 2016
Science 37 , 2015
ePharmaSolutions, 2014
Medidata Solutions , 2013
For more information, please contact [email protected] or visit dpharmconference.com.
founder at Wellville
1 年I'm biased, but this is my absolute favorite part of #DPHARM every year! Candid appraisals of the best the industry has to offer.